HC Wainwright reiterated their hold rating on shares of DENTSPLY SIRONA (NASDAQ:XRAY) in a report released on Thursday. They currently have a $68.00 price objective on the medical instruments supplier’s stock.

A number of other brokerages have also recently issued reports on XRAY. Stephens assumed coverage on DENTSPLY SIRONA in a research note on Tuesday, November 28th. They set an overweight rating and a $75.00 price objective for the company. BidaskClub lowered DENTSPLY SIRONA from a strong-buy rating to a buy rating in a report on Saturday, December 2nd. Barrington Research raised DENTSPLY SIRONA from a market perform rating to an outperform rating and set a $73.00 target price for the company in a report on Monday, November 6th. TheStreet raised DENTSPLY SIRONA from a c rating to a b- rating in a report on Friday, November 3rd. Finally, Stifel Nicolaus lifted their target price on DENTSPLY SIRONA from $66.00 to $70.00 and gave the stock a buy rating in a report on Monday, November 6th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $68.83.

Shares of DENTSPLY SIRONA (NASDAQ XRAY) traded down $0.09 during trading hours on Thursday, reaching $64.90. The company’s stock had a trading volume of 1,957,665 shares, compared to its average volume of 1,653,382. The stock has a market capitalization of $15,044.23, a PE ratio of 26.10, a price-to-earnings-growth ratio of 2.59 and a beta of 1.31. DENTSPLY SIRONA has a 1-year low of $52.53 and a 1-year high of $68.98. The company has a quick ratio of 1.59, a current ratio of 2.32 and a debt-to-equity ratio of 0.21.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.04. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $978.99 million. DENTSPLY SIRONA had a positive return on equity of 7.56% and a negative net margin of 20.33%. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.66 earnings per share. sell-side analysts predict that DENTSPLY SIRONA will post 2.66 EPS for the current fiscal year.

In other DENTSPLY SIRONA news, CFO Nicholas W. Alexos bought 50,000 shares of DENTSPLY SIRONA stock in a transaction on Monday, November 13th. The stock was acquired at an average price of $65.85 per share, with a total value of $3,292,500.00. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Francis J. Lunger sold 8,900 shares of DENTSPLY SIRONA stock in a transaction on Monday, November 13th. The stock was sold at an average price of $65.90, for a total value of $586,510.00. The disclosure for this sale can be found here. 1.99% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Commonwealth Bank of Australia grew its holdings in shares of DENTSPLY SIRONA by 19.0% in the second quarter. Commonwealth Bank of Australia now owns 1,626 shares of the medical instruments supplier’s stock worth $104,000 after acquiring an additional 260 shares during the period. Acrospire Investment Management LLC bought a new stake in shares of DENTSPLY SIRONA in the second quarter worth $113,000. Dupont Capital Management Corp bought a new stake in shares of DENTSPLY SIRONA in the second quarter worth $116,000. Massey Quick Simon & CO. LLC bought a new stake in shares of DENTSPLY SIRONA in the third quarter worth $124,000. Finally, Korea Investment CORP grew its holdings in shares of DENTSPLY SIRONA by 139.9% in the second quarter. Korea Investment CORP now owns 2,145 shares of the medical instruments supplier’s stock worth $139,000 after acquiring an additional 1,251 shares during the period. 96.58% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “DENTSPLY SIRONA’s (XRAY) Hold Rating Reaffirmed at HC Wainwright” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/dentsply-sironas-xray-hold-rating-reaffirmed-at-hc-wainwright/1752551.html.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.